Drug analysis

A
B-C
D-F
Drug Analysis
G-L
M-O
P-R
S-T
U-Z

Text search

Sort by Price

Click to order products ascending

Display 30 Products per page

Midostaurin
Read More
Midostaurin is a multiple kinase inhibitor, which interferes with cellular signal transduction pathways. While the drug exhibits efficacy against a number of kinases, its efficacy against FLT3 is of particular relevance to AML.
April 22, 2014
Find out more
Teflaro
Read More
Teflaro (ceftaroline fosamil; Actavis/AstraZeneca/Dainippon Sumitomo Pharma) is a fifth-generation cephalosporin.
September 29, 2016
Find out more
Tivantinib
Read More
Tivantinib (ArQule/Daiichi Sankyo/Kyowa Hakko Kirin) is an orally available small molecule inhibitor of the hepatocyte growth factor (HGF) receptor, c-MET.
December 31, 2015
Find out more
Neratinib
Read More
Neratinib (Puma Biotechnology) is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the human epidermal growth factor receptor (HER)1, HER2, HER4, and epidermal growth factor receptor kinases.
March 9, 2015
Find out more
Peretinoin
Read More
Peretinoin (Kowa/Chugai Pharmaceutical) is a synthetic acyclic retinoid inhibitor of transforming growth factor alpha (TGF-alpha) and platelet-derived growth factor receptor (PDGFR). TGF-alpha induces epithelial development, and is closely involved in hepatocarcinogenesis.
December 31, 2015
Find out more
Vibativ
Read More
Vibativ is a lipoglycopeptide antibiotic that is a semisynthetic derivative of vancomycin. The drug exhibits a dual bactericidal mechanism of action.
September 10, 2014
Find out more
ProstAtak
Read More
ProstAtak (AdV-tk + valacyclovir) is a viral cancer vaccine being developed by Advantagene for the treatment of prostate cancer. It works by gene-mediated cytotoxic immunotherapy, an approach that generates a tumor-specific vaccine.
September 24, 2015
Find out more
Sarilumab
Read More
Sarilumab (Sanofi/Regeneron) is a human monoclonal antibody interleukin (IL)-6 receptor antagonist in Phase III development for rheumatoid arthritis.
March 24, 2015
Find out more
Sirukumab
Read More
Sirukumab (CNTO 136; Janssen/GlaxoSmithKline) is a human monoclonal antibody interleukin-6 receptor antagonist that is currently in Phase III development for rheumatoid arthritis.
March 24, 2015
Find out more
Sivextro
Read More
Sivextro is a second-generation oxazolidinone, while tedizolid phosphate is a prodrug that is cleaved in the bloodstream to the active antibiotic tedizolid. The active moiety tedizolid inhibits bacterial protein synthesis by interacting with the bacterial 23S ribosome initiation complex.
September 10, 2014
Find out more
solithromycin
Read More
Solithromycin (Cempra Pharmaceuticals/Cubist Pharmaceuticals/Toyama Chemical) is a next-generation ketolide antibiotic. The drug, which is structurally related to the macrolide class of antibiotics, is the first fluoroketolide antibacterial in clinical development for bacterial infections, including CAP.
June 19, 2015
Find out more
Spectracef
Read More
Spectracef (cefditoren pivoxil; Vansen Pharma) is an oral semisynthetic, broad-spectrum, third-generation cephalosporin. After oral administration, the pro-drug, cefditoren pivoxil, is converted to the active drug, cefditoren, through esterase hydrolysis.
June 19, 2015
Find out more
Zeftera
Read More
Zeftera (ceftobiprole medocaril; Basilea Pharmaceutica) is a novel intravenous broad-spectrum fifth-generation cephalosporin.
June 19, 2015
Find out more
Zelapar
Read More
Zelapar (selegiline; Valeant) is a novel rapidly disintegrating tablet formulation of the monoamine oxidase B (MAO-B) inhibitor selegiline.
October 24, 2014
Find out more
Zyvox
Read More
Pfizer developed Zyvox (linezolid) as the first oxazolidinone antimicrobial agent. The drug gained its first regulatory approval for the treatment of complicated skin and skin structure infections (cSSSI) in the US market in 2000.
June 19, 2015
Find out more
ABBV-066
Read More
ABBV-066 (risankizumab; AbbVie/Boehringer Ingelheim) is a humanized anti-interleukin(IL)-23 subunit p19 monoclonal antibody that binds and neutralizes the p19 subunit of IL-23.
August 26, 2016
Find out more
Aducanumab
Read More
Aducanumab (Biogen/Eisai) is an intravenous-infused, fully human recombinant immunoglobulin G1 monoclonal antibody.
September 29, 2016
Find out more
AGS-003
Read More
AGS-003 (Argos Therapeutics/Kyowa Hakko Kirin) is a cancer vaccine in development for the first-line treatment of metastatic renal cell cancer (RCC) in combination with Sutent (sunitinib; Pfizer).
February 5, 2016
Find out more
Bax 817
Read More
BAX 817 is an rfVIIa therapy in development by Baxalta for patients with hemophilia A or B with inhibitors. FVIIa therapy can circumvent the need for fVIII and fIX in the coagulation cascade by directly activating factor X…
March 14, 2016
Find out more
Betrixaban
Read More
Betrixaban (Portola Pharmaceuticals) is an oral, once-daily inhibitor of factor Xa that catalyzes conversion of prothrombin to thrombin, preventing thrombosis. Betrixaban is currently in Phase III development…
August 2, 2016
Find out more
blisibimod
Read More
Blisibimod is a selective antagonist of B-cell activating factor (BAFF)/B lymphocyte stimulator (BLyS) that is in Phase III development for SLE. Elevated levels of BAFF have also been associated with several B-cell-mediated autoimmune diseases including…
April 5, 2016
Find out more
Bococizumab
Read More
Bococizumab is an antidyslipidemic humanized antibody that inhibits PCSK9. PCSK9 is a protease involved in the intracellular and extracellular regulation of LDL receptor (LDLR) expression…
June 29, 2016
Find out more
Brilinta
Read More
Brilinta (ticagrelor; AstraZeneca/The Medicines Company) is an antiplatelet agent designed to inhibit blood clot formation. It works by reversibly binding to the blood platelets’ adenosine diphosphate (ADP) P2Y12 receptor…
April 14, 2016
Find out more
Brintellix
Read More
Brintellix (vortioxetine; Lundbeck/Takeda) is the latest antidepressant to be approved in the US for major depressive disorder. The drug follows a successful line of antidepressants developed by Lundbeck, which includes Cipralex (escitalopram) and Cipramil (citalopram).
May 5, 2016
Find out more
Briviacti
Read More
Briviact (brivaracetam; UCB) is a follow-on product to Keppra (levetiracetam; UCB/Otsuka), acting as an anticonvulsant by binding to the synaptic vesicle glycoprotein 2A (SV2A), directly causing…
June 7, 2016
Find out more
Buparlisibi
Read More
Buparlisib is a pan-PI3K inhibitor that attempts to counteract the dysregulation of the PI3K/protein kinase B (AKT) pathway in cancerous tissues…
May 2, 2016
Find out more
DCVax-L
Read More
DCVax-L (Northwest Biotherapeutics) is a dendritic cell vaccine in development for the treatment of glioblastoma multiforme (GBM). It is a personalized immunotherapy that utilizes patients’ own dendritic cells to stimulate…
April 13, 2016
Find out more
Dovobet
Read More
Leo Pharma developed and launched Dovobet (also known as Daivobet, Taclonex, Xamiol, and LEO-80185), a dermatological ointment formulation of the vitamin D analog calcipotriol and the corticosteroid betamethasone dipropionate, for the treatment of…
August 28, 2016
Find out more
Dovonex
Read More
Dovonex, a topical vitamin D derivative, reduces excessive skin cell production and therefore helps improve the symptoms of psoriasis. It is sold under the brand name Daivonex in certain European, South American, and Asian markets…
August 26, 2016
Find out more
Faslodex
Read More
Faslodex (fulvestrant; AstraZeneca) is an analog of 17 beta-estradiol, the dominant circulating estrogen, which competitively inhibits the binding of natural estradiol to the estrogen receptor (ER).
February 2, 2016
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Call Back

Name

Email *

Company name *

Phone number *